Abstract:Background: beta-Amyloid (A beta) fibrillation is critical for A beta deposition and cytotoxicity during the progression of Alzheimer's disease (AD). Consequently, anti-A beta monoclonal antibody drugs targeting A beta oligomers and aggregation are considered potential therapeutic strategies for AD treatment. Similar to the working mechanisms of anti-A beta monoclonal antibody drugs, our study identified osmundacetone (OAC), a small-molecule compound isolated from the traditional Chinese medicine Rhizoma Osmundae, as exerting anti-AD effects by targeting A beta. Purpose: This study sought to determine whether OAC influences the A beta burden in APP/PS1 mice and to identify potential regulatory mechanisms. Methods: Five-month-old APP/PS1 mice were injected intraperitoneally with OAC at a dose of 1 mg/kg for 12 weeks. The cognitive functions of the mice were assessed via the Morris water maze test and the open field test. Osmundacetone was analyzed via molecular docking, an isothermal dose-response fingerprint-cellular context thermal shift assay, a thioflavine T fluorescence assay, and an atomic force microscopy assay to analyze the effects of OAC on A beta fibrillation. Immunofluorescence, immunoblotting, and immunohistochemistry were used to assess A beta clearance, AD pathology, oxidative stress, and inflammatory responses. Results: The innovative biochemical and physical data illustrated that the ability of OAC to inhibit A beta fibrillation was accomplished by binding directly to A beta, which differed from the majority of previously reported natural polyphenols that modulate the A beta content and structure in an indirect manner. The inhibition of A beta fibrosis by OAC subsequently promoted A beta lysosomal degradation, resulting in a decreased A beta burden in APP/PS1 mice. Furthermore, OAC treatment inhibited oxidative damage by upregulating glutathione peroxidase expression and attenuated the production of inflammatory factors by downregulating nuclear factor-kB phosphorylation in APP/ PS1 mice. Conclusion: These findings demonstrate, for the first time, that OAC could reduce the brain A beta burden in APP/PS1 mice by inhibiting A beta fibrillation through direct binding to A beta and improve cognitive dysfunction by attenuating oxidative damage and neuroinflammation. These findings indicate that OAC may be a promising candidate for the treatment of AD.

Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus

Thiamme2-G, a Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice

Overview of a novel osmotin abolishes abnormal metabolic-associated adiponectin mechanism in Alzheimer's disease: Peripheral and CNS insights

Osmundacetone Ameliorates Alzheimer's-like Pathologies by Inhibiting (3-Amyloid Fibrillation, Oxidative Damage and Neuroinflammation in APP/ PS1 Transgenic Mice

Osmundacetone ameliorates Alzheimer's-like pathologies by inhibiting β-amyloid fibrillation, oxidative damage and neuroinflammation in APP/PS1 transgenic mice

Neuroprotective Effects of N-methyl-(2S, 4R)-trans-4-hydroxy-L-proline (NMP) against Amyloid-β-Induced Alzheimer's Disease Mouse Model

Long-term oral administration of hyperoside ameliorates AD-related neuropathology and improves cognitive impairment in APP/PS1 transgenic mice

Morinda Officinalis Oligosaccharides Alleviate Cognitive Dysfunction Through Depressing Β-Amyloid Deposition and ER Stress in Alzheimer'S Disease

Cross-Interplay between Osmolytes and mTOR in Alzheimer's Disease Pathogenesis

Osteocalcin Ameliorates Cognitive Dysfunctions in a Mouse Model of Alzheimer’s Disease by Reducing Amyloid Β Burden and Upregulating Glycolysis in Neuroglia

Osteocalcin ameliorates cognitive dysfunctions in a mouse model of Alzheimer's Disease by reducing amyloid β burden and upregulating glycolysis in neuroglia

N-Acetyl Chitooligosaccharides Attenuate Amyloid Β-Induced Damage in Animal and Cell Models of Alzheimer’s Disease

An 18-mer Peptide Derived from Prosaposin Ameliorates the Effects of Aβ1-42 Neurotoxicity on Hippocampal Neurogenesis and Memory Deficit in Mice.

Proteomic insights into early-stage Alzheimer's disease: Identifying key neuronal proteins impacted by amyloid beta oligomers in an in vitro model

Transferrin-Modified Osthole PEGylated Liposomes Travel the Blood-Brain Barrier and Mitigate Alzheimer’s Disease-Related Pathology in APP/PS-1 Mice

Ovocystatin Induced Changes in Expression of Alzheimer’s Disease Relevant Proteins in APP/PS1 Transgenic Mice

Sovateltide (IRL‐1620) prevents oxidative damage, mitochondrial dysfunction, and memory loss in a transgenic mouse model of Alzheimer’s disease

Oolonghomobisflavans from disaggregate tau fibrils across Alzheimer’s disease models

Sodium tanshinone IIA sulfonate improves cognitive impairment via regulating Aβ transportation in AD transgenic mouse model

Effect of outer membrane vesicles of Lactobacillus pentosus on Tau phosphorylation and CDK5-Calpain pathway in mice

Tetrahydroxy stilbene glycoside (TSG) antagonizes Aβ-induced hippocampal neuron injury by suppressing mitochondrial dysfunction via Nrf2-dependent HO-1 pathway.